The VHL (von Hippel-Lindau) disease is the most clinically significant hereditary renal mass syndrome and carries a major GP recognition responsibility — VHL is an autosomal dominant tumour suppressor gene mutation on chromosome 3p that predisposes to: bilateral, multifocal clear cell RCC (often presenting early, age 20s-30s); cerebellar and spinal cord haemangioblastomas; retinal haemangiomas (presenting as visual symptoms); phaeochromocytomas; endolymphatic sac tumours (hearing loss); pancreatic cysts and neuroendocrine tumours. The typical presentation: a young adult with bilateral or multifocal renal cysts/masses, with or without family history. The critical management implication: VHL RCCs require nephron-sparing surgery wherever possible (partial nephrectomy) to preserve renal function given the bilateral and recurrent nature of the disease. NICE NG256 recommends hereditary assessment for people aged 46 or younger, with multiple renal tumours, a first- or second-degree relative with renal cancer, features of a hereditary syndrome or associated histology — refer via the local clinical-genetics pathway and to specialist RCC centres for surgical planning.

The Bosniak classification is the universally used radiological risk stratification system for incidentally discovered renal cysts — it was developed by Dr Morton Bosniak (1986, updated 2019) as a CT-based scoring system. The 2019 update to the Bosniak classification (version 2019) refined the categories with more precise CT morphological criteria, particularly distinguishing Bosniak IIF from III based on the number of septa, calcification pattern, and contrast enhancement. For GPs: the practical application is that the radiology report from an incidental finding on CT or USS will often include a Bosniak category, and the GP's role is to act on that categorisation: Bosniak I-II = no action; Bosniak IIF = secondary-care active surveillance with a documented plan; Bosniak III-IV = prompt urology/uro-oncology referral for MDT review. A key practical pitfall: USS cannot reliably classify Bosniak category — any indeterminate cystic renal lesion on USS requires specialist-directed multiphasic CT or MRI for accurate Bosniak classification before clinical decision-making.

The paraneoplastic syndromes of renal cell carcinoma are important clinical red flags that GPs may encounter without realising the significance — RCC is one of the most prolific producers of paraneoplastic phenomena in oncology. The key syndromes to recognise: (1) Polycythaemia — elevated haemoglobin/haematocrit from ectopic EPO production; (2) Hypercalcaemia — PTHrP production causing symptomatic hypercalcaemia (confusion, polydipsia, constipation, weakness) without bone metastases; (3) Stauffer syndrome — reversible hepatic dysfunction (elevated ALP, GGT, ferritin) in the absence of liver metastases, caused by hepatocyte-affecting cytokines from the primary tumour; it resolves after nephrectomy and recurs with metastatic relapse (therefore an excellent follow-up marker); (4) Hypertension from ectopic renin; (5) Amyloid (secondary, AA-type). These associations are not specific enough to justify a routine "paraneoplastic screen" in every incidental mass; investigate unexplained polycythaemia or hypercalcaemia through standard pathways (corrected calcium, PTH, renal function and clinical context). Stauffer syndrome is a specialist diagnosis.

The renal mass biopsy paradigm shift represents a significant change from the historical approach of treating all solid enhancing renal masses as malignant until proved otherwise — traditionally, a solid enhancing renal mass led directly to surgery (radical or partial nephrectomy) without histological confirmation. This approach carried a benign surgical rate of approximately 20-25% — meaning 1 in 4-5 nephrectomies were for benign conditions (oncocytoma, AML, lipid-poor AML). Image-guided renal mass biopsy (core biopsy, 18G needle, 2 cores minimum) has a diagnostic accuracy of approximately 90-95% and a very low complication rate. NICE NG256 (2026): offer biopsy for lesions ≤4 cm with a sufficient solid component where it could influence management, and before thermal ablation or SABR unless specialist circumstances dictate otherwise. GPs should understand that 'biopsy first, then treat' is increasingly standard practice at specialist RCC centres.

Benign lesions such as angiomyolipoma (AML) are generally managed outside the cancer pathway (NICE NG256). AML can bleed spontaneously (Wunderlich syndrome — acute flank pain, shock and falling haemoglobin), but current evidence does not support treating every AML over 4 cm. Most sporadic AMLs can be managed with specialist surveillance; active treatment — selective arterial embolisation, nephron-sparing surgery or, in selected tuberous-sclerosis-related disease, systemic therapy — is discussed for persistent pain, acute/recurrent bleeding, high-risk vascular features, substantial growth, very large tumour burden, pregnancy/childbearing considerations or other patient-specific risk. AML in tuberous sclerosis complex (TSC): often bilateral, multiple, large, and rapidly growing — requires specialist TSC centre review for mTOR inhibitor treatment (everolimus reduces AML size by approximately 50%). Any patient with TSC and renal lesions requires nephrology-urology co-management.

The post-nephrectomy CKD surveillance responsibility in primary care is an important and frequently overlooked aspect of RCC aftercare — approximately 25-30% of patients who undergo radical nephrectomy develop CKD stage 3 or worse within 5 years. The eGFR decline after nephrectomy is not just a quality-of-life issue — it is a cardiovascular risk factor. Multiple studies have shown that post-nephrectomy CKD increases cardiovascular mortality more than the cancer itself in T1-T2 RCC patients. The GP's role in post-nephrectomy follow-up: (1) Annual eGFR monitoring; (2) Blood pressure and cardiovascular risk optimised per standard hypertension/CKD guidance (ACEi/ARB where clinically indicated, particularly with albuminuria); (3) ACR if eGFR is below 60 or there is proteinuria (NICE NG256); (4) Lifestyle: salt restriction, smoking cessation, weight management; (5) Avoid unnecessary or prolonged NSAID use, particularly in CKD, dehydration or intercurrent illness; contrast decisions follow radiology/renal guidance — an eGFR check should not delay necessary cancer imaging.

The immune checkpoint inhibitor adverse effects (immune-related adverse events — irAEs) require prompt GP recognition and escalation in patients receiving immunotherapy for RCC — nivolumab, pembrolizumab, and ipilimumab activate T-cell responses against tumour antigens but can also trigger autoimmune inflammation in any organ system. Urgently contact the oncology team or arrange same-day assessment for: new or worsening diarrhoea or abdominal pain; cough, dyspnoea or hypoxia; jaundice or markedly abnormal liver tests; severe headache, visual symptoms or confusion; profound fatigue, hypotension or suspected adrenal crisis; polyuria, polydipsia or suspected immune-mediated diabetes; chest pain, palpitations or new neurological symptoms; severe rash or mucosal involvement. Do not start corticosteroids or stop immunotherapy without specialist input unless managing a medical emergency under the local protocol. GPs should be alert to any new symptoms in immunotherapy patients that could represent an irAE — these require urgent oncology team contact, not a 'wait and see' approach.

The 'scanxiety' phenomenon (anxiety surrounding surveillance imaging appointments) is a significant quality-of-life impairment for RCC survivors that is commonly underacknowledged — studies show that approximately 50-60% of cancer survivors experience clinically significant anxiety in the days and weeks before surveillance CT appointments. For RCC patients, who typically undergo CT surveillance every 6-12 months for 5 years, this creates a recurring cycle of anxiety that can profoundly affect daily functioning. GPs can help by: (1) proactively asking about anxiety at surveillance appointment times; (2) providing clear written information about what the follow-up CT is checking for and what the procedure involves; (3) confirming that results will be communicated promptly after the scan (delayed results amplify anxiety); (4) offering CBT referral for clinically significant surveillance anxiety. Acceptance and Commitment Therapy (ACT) has specific evidence for cancer-related anxiety and scanxiety.

The annual eGFR + blood pressure monitoring after nephrectomy represents a simple but high-impact GP intervention — the evidence consistently shows that the largest driver of mortality in T1-T2 RCC survivors (who have excellent cancer-specific survival exceeding 90% at 5 years) is cardiovascular disease, not cancer recurrence. The post-nephrectomy CKD is an independent cardiovascular risk factor: eGFR below 45 mL/min is associated with approximately 2-fold increased risk of major cardiovascular events (MI, stroke, heart failure). GPs who monitor eGFR annually, treat hypertension to target, and address proteinuria in post-nephrectomy patients are directly preventing the leading cause of death in this population — which is more impactful, from a population health perspective, than monitoring for cancer recurrence.